Eli Lilly's weight-loss drug Foundyo has received its first approval outside the United States, securing authorization in the United Kingdom and expanding the company's competition with Novo Nordisk's Wegovy.
Impact: The U.K. approval is likely to lift Lilly's share price as it opens a new market for its obesity franchise.
Not investment advice